<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03008850</url>
  </required_header>
  <id_info>
    <org_study_id>Shivering, MgSO4</org_study_id>
    <nct_id>NCT03008850</nct_id>
  </id_info>
  <brief_title>Shivering Prevention During Cesarean Section by Intrathecal Injection of Magnesium Sulfate</brief_title>
  <official_title>Shivering Prevention During Cesarean Section by Intrathecal Injection of Magnesium Sulfate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shivering is a common post-anesthetic complication occurring in up to 65% of patients&#xD;
      undergoing spinal or epidural anesthesia. Shivering may interfere with electrocardiogram,&#xD;
      blood pressure and oxygen saturation monitoring. In addition, shivering increases oxygen&#xD;
      consumption, carbon dioxide production and metabolic rate by up to 400%. Thus, it may result&#xD;
      in problems in patients with low cardiac and pulmonary reserves. Preventing shivering could&#xD;
      therefore result in better postoperative outcomes or reduce the incidence of post-surgical&#xD;
      complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnesium sulfate (MgSO4) has anti-shivering effects. Moreover, it has potential&#xD;
      neuroprotective effects and may enhance neuroprotection against the effects of hypothermia.&#xD;
      Intrathecal MgSO4 administration provides effective perioperative analgesia and can prolong&#xD;
      the period of anesthesia and sensory blockade without any additional side-effects. However,&#xD;
      most of the research on the role of MgSO4 in the prevention of shivering has focused on&#xD;
      intravenous infusion of this drug. Few clinical trials have examined the effect of adding&#xD;
      intrathecal MgSO4 to anesthetic agents such as bupivacaine to suppress anesthesia-related&#xD;
      shivering in patients. Similar to infusion studies, we hypothesized that the addition of&#xD;
      intrathecal injection of MgSO4 to bupivacaine would improve perioperative shivering in female&#xD;
      patients undergoing elective caesarean section. Few previous studies evaluated neuroaxial&#xD;
      anti-shivering effects of intrathecal magnesium and none evaluated the anti-shivering effect&#xD;
      of intrathecal MgSO4. Therefore, we elected to use the lowest dosage (25 mg MgSO4) that was&#xD;
      formerly utilized for investigation of analgesic effects.&#xD;
&#xD;
      Magnesium sulphate is an intracellular cation with various physiologic functions such as&#xD;
      enzyme activation, nerve signal conduction, protein synthesis and vasomotor tonicity&#xD;
      regulation. Magnesium sulphate has been used in various clinical situations including&#xD;
      preeclampsia, tocolysis, arrhythmias, myocardial ischemia, bronchial asthma and postoperative&#xD;
      shivering.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Shivering Score</measure>
    <time_frame>2 hours</time_frame>
    <description>shivering will be recorded in the recovery room for 2 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Pain Score</measure>
    <time_frame>2 hours</time_frame>
    <description>analgesics will be given if visual analogue score ≥ 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>2 hours</time_frame>
    <description>percentage of patients with any complications will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Cesarean Section; Shivering</condition>
  <arm_group>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MgSo4</intervention_name>
    <description>Patients will be randomly allocated to one of two groups:&#xD;
Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.&#xD;
Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally.</description>
    <arm_group_label>Group M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will be randomly allocated to one of two groups:&#xD;
Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.&#xD;
Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally.</description>
    <arm_group_label>Group P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 35years.&#xD;
&#xD;
          2. Undergo elective cesarean section under spinal anesthesia.&#xD;
&#xD;
          3. ASA physical status I-II.&#xD;
&#xD;
          4. Singleton pregnancy.&#xD;
&#xD;
          5. At least 38 weeks gestation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women with history of cardiac, liver or kidney diseases.&#xD;
&#xD;
          2. Women with allergy to amide local anesthetics or medication included in the study.&#xD;
&#xD;
          3. Women with any neurological problem.&#xD;
&#xD;
          4. Any contraindication of regional anesthesia.&#xD;
&#xD;
          5. Failed or insatisfactory spinal block.&#xD;
&#xD;
          6. Preoperative temperature more than 38⁰ C.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zain E. Hassan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospital</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>December 27, 2016</study_first_submitted>
  <study_first_submitted_qc>December 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2017</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>MOHAMED F. MOSTAFA</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>Shivering</keyword>
  <keyword>Intrathecal</keyword>
  <keyword>Magnesium Sulfate</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

